RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
more
Stories about Pharmakologie
Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
moreAccord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
moreStrides Pharma International AG
Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
moreInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies
more- 2
SHL Medical announces plans to establish SHL Advantec
more
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
moreFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
moreEvent Announcement: VIROFIGHT Hybrid Symposium
One documentmoreEpitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference
Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...
morePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
moreNorgine Announces Appointment of New CEO Janneke van der Kamp
London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...
more
RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
moreEpitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
more- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore INSIGHTEC; Charles River Laboratories International, Inc.
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
more- 2
Record financing rounds at the Munich biotech hub
One documentmore Press release: STADA continues strong growth journey in the first half of 2024
One documentmore
Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
more- 2
Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients
more - 10
Gerresheimer: New pictures available
more Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmore
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore Press release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmore- 2
Gerresheimer partners with RxCap to offer connected adherence solutions
more Bosch Healthcare Solutions GmbH
Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform
Darmstadt, Gerlingen, and Waiblingen, Germany (ots) - Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria - Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. - PCR test for multiresistant gram-negative (MRGN) ...
moreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
more
Previous123456Next